< Terug naar vorige pagina

Publicatie

One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020

Tijdschriftbijdrage - Tijdschriftartikel

Ondertitel:a systematic review
Background: Hepatitis A virus (HAV) is a global health concern as outbreaks continue to occur. Since 1999, several countries have introduced universal vaccination (UV) of children against HAV according to approved two-dose schedules. Other countries have implemented one-dose UV programs since 2005; the long-term impact of this schedule is not yet known. Methods: We conducted a systematic literature search in four electronic databases for data published between January 2000 and July 2019 to assess evidence for one-dose and two-dose UV of children with non-live HAV vaccines and describe their global impact on incidence, mortality, and severity of hepatitis A, vaccine effectiveness, vaccine efficacy, and antibody persistence. Results: Of 3739 records screened, 33 peer-reviewed articles and one conference abstract were included. Rapid declines in incidence of hepatitis A and related outcomes were observed in all age groups post introduction of UV programs, which persisted for at least 14 years for two-dose and six years for one dose programs according to respective study durations. Vaccine effectiveness was >95% over 3-5 years for two-dose programs. Vaccine efficacy was >98% over 0.1-7.5 years for one-dose vaccination. Antibody persistence in vaccinated individuals was documented for up to 15 years (>90%) and ten years (>74%) for two-dose and one-dose schedules, respectively. Conclusion: Experience with two-dose UV of children against HAV is extensive, demonstrating an impact on the incidence of hepatitis A and antibody persistence for at least 15 years in many countries globally. Because evidence is more limited for one-dose UV, we were unable to draw conclusions on immune response persistence beyond ten years or the need for booster doses later in life. Ongoing epidemiological monitoring is essential in countries implementing one-dose UV against HAV. Based on current evidence, two doses of non-live HAV vaccines are needed to ensure long-term protection. (c) 2021 GSK. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
Tijdschrift: Vaccine
ISSN: 0264-410X
Volume: 40
Pagina's: 196 - 205
Jaar van publicatie:2022
Trefwoorden:A1 Journal article
Toegankelijkheid:Open